CDKL5-Deficient Neuron Models for Rescuing Cellular Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CDKL5 deficiency disorder (CDD) lack effective therapies, and existing rodent models fail to consistently replicate the human condition, including spontaneous seizures, making it challenging to develop robust therapeutic strategies.
Innovation Solution
A human stem cell-based model is developed using CDKL5-deficient cells to understand the disorder's complex phenotypes, and a drug screening platform is implemented using 3D neural spheroids to identify therapeutic compounds that can rescue deleterious biological effects, focusing on Ivabradine, Solifenacin, AZD1080, and Crenigacestat as potential treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rodent models are used to study CDD, then research can be conducted with available animal models, but the models fail to consistently replicate human spontaneous seizures and disease phenotypes
Solution Approach 1:
The patent creates human iPSC-derived neuronal models that copy human disease phenotypes more accurately than rodent models. By using patient-derived induced pluripotent stem cells differentiated into neurons, the system replicates human-specific disease characteristics including spontaneous seizures, providing a more reliable human-relevant model for CDD research and drug screening.
2Ease of manufacture
If conventional treatments are administered for CDD, then standard epilepsy protocols are followed, but effective therapies are lacking for this specific disorder
Solution Approach 1:
The patent employs high-throughput screening to identify compounds that specifically modulate neuronal excitability parameters in CDD models. By systematically testing multiple compounds against human iPSC-derived neurons exhibiting CDD phenotypes, the approach discovers novel therapeutic agents (such as ivabradine and solifenacin) that directly address the underlying pathophysiology rather than applying generic epilepsy treatments.
3Measurement precision
If human iPSC-derived neuronal models are developed, then accurate human disease phenotypes can be studied, but the complexity of the model system increases
Solution Approach 1:
The patent segments the complex human disease model into manageable components by deriving specific neuronal types from iPSCs and culturing them in controlled in vitro systems. This segmentation allows researchers to study specific aspects of CDD pathology (such as neuronal excitability, network synchronization, and drug responses) in isolation while maintaining human-relevant phenotypes, thereby reducing overall system complexity while preserving measurement precision.
Data Source
AI summary
The disclosure provides methods for rescuing defects caused by abnormal CDKL5 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, a muscarinic receptor inhibitor, a GSK3 inhibitor, a Notch inhibitor and any combination thereof. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, CDKL5-mosaic neurospheres, and cortical organoids).